HIV暴露前预防:现在与未来扩大规模以产生影响
口服HIV暴露前预防(PrEP)有效性证据报告十余年后,全球PrEP uptake仍不足且未达预防目标,获取集中在少数国家且国家内存在不平等。文章主张设定更进取的全球PrEP目标、建设PrEP友好卫生系统、推进去医疗化模型,并关注个体障碍与新型PrEP模式下的长期使用模式。
要点
- 全球PrEP uptake不足且高度集中于少数国家,国家内亦存在不平等。
- 需设定更进取的全球PrEP目标以加速HIV预防响应。
- 卫生系统应PrEP友好,在HIV阴性高风险人群就诊场景中提供PrEP。
核心结论
- 扩大PrEP对实现联合国艾滋病规划署2030年预防目标至关重要,但成功应以对HIV流行的影响而非仅入组人数衡量。
研究设计与样本
- 本文为Lancet Public Health发表的评论/综述性文章,未报告原始研究样本量与检索范围。
主要发现
- 口服PrEP首项有效性证据报告十余年后,全球PrEP uptake不足且全球HIV预防目标未达成。
- PrEP获取仍高度集中在少数国家,即使在PrEP广泛可及的国家内也出现不平等。
- 个体层面障碍包括低认知、低使用意愿及自感HIV风险与实际风险之间的差距。
- 新型PrEP模式正在出现,需理解不同人群中PrEP长期使用模式并建立可容纳间歇使用与方案切换的模型。
关键数值与推荐
- 文章呼吁设定更进取、高优先级的全球PrEP uptake目标,类比90-90-90检测治疗目标的成功。
- 文章主张卫生系统应PrEP友好,允许在大量HIV阴性高风险个体已就诊的场景中开具PrEP。
- 文章提出多种PrEP去医疗化模型,但未报告具体阈值、剂量或比例数值。
临床怎么用
- 在HIV阴性高风险人群已就诊的场所提供PrEP处方,降低获取门槛。
- 识别并干预低认知、低意愿及自感风险偏低等个体障碍以提升PrEP启动与坚持。
- 监测不同人群中PrEP间歇使用与方案/模式切换的长期模式,以评估项目对HIV流行的影响。
局限性
- 本文为评论/综述性文章,未报告原始研究样本量、效应量或检索策略。
- 文章未提供具体国家层面的PrEP uptake数值或不平等量化指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More than a decade after the first efficacy evidence for oral HIV pre-exposure prophylaxis (PrEP) was reported, PrEP uptake globally has been inadequate and global HIV prevention targets have been missed. Access to PrEP is still highly concentrated in a fairly small number of countries and, even within countries with widespread PrEP access, inequalities have emerged. More ambitious, high-priority global targets for PrEP uptake are required and could accelerate the HIV prevention response in a similar way to the success of the 90-90-90 testing and treatment targets. Health systems must be PrEP-friendly and allow PrEP to be prescribed in settings already attended by large numbers of HIV-negative individuals who are at risk. Several models have been advanced for the greater demedicalisation of PrEP. Individual-level barriers to PrEP uptake and persistence have been characterised, such as low awareness, low willingness to use PrEP, and the gap between self-perceived and actual HIV risk. Overcoming these barriers will require further efforts to understand and address them first. New PrEP modalities are emerging; as more options become available, we need to develop a greater understanding of the long-term patterns of PrEP use in different populations and to develop models of such use that can accommodate people alternating through periods of use and non-use, as well as switching between dosing regimens or modalities as they become available. Scaling up PrEP is crucial to achieving the UNAIDS prevention targets for 2030. Simply getting more people onto PrEP cannot be the only goal: the big-picture definition of success for PrEP programmes must be their impact on the HIV epidemic.
引用
- Bavinton BR, Grulich AE. HIV pre-exposure prophylaxis: scaling up for impact now and in the future. Lancet Public Health. 2021. PMID: 34087117. doi:10.1016/S2468-2667(21)00112-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。